Consolidation in big pharma/biotech continues with Abbott and Solvay Pharmaceuticals

Despite the economic downturn that first reared its ugly head in 2008, the pharma and biotech industries have seen M&A activity consistent with the burgeoning economy of the late 1990s. The past year has witnessed Merck's $41 billion bid for Schering-Plough, a $47 billion bid on Genentech from Roche...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Breakthrough Energy Ventures raises second $1 billion fund, targeting 40 to 50 startups with emphasis on hard-to-decarbonize sectors

News Commentary | January 19, 2021

Since its first fund in 2015, BEV has invested in 30 startups across a range of technology areas. Key startups backed by BEV include Boston Metal, CarbonCure, Pivot Bio, Form Energy, and Nature's Fynd. With the recent SPAC craze driving up valuations of startups in the cleantech space, there is ... Not part of subscription

Overzealous investors will drive cleantech startup valuations in 2021; clients advised to practice more caution in strategic investments

News Commentary | January 22, 2021

Thomson Reuters reported that the share prices of green hydrogen companies have risen by more than 500%, with companies like Plug Power, Ceres Power, and FuelCell Energy headlining the rise. Cleantech ETFs have also grown by up to 200% in the same period as investor interest in cleantech continues ... Not part of subscription

Another multibillion-dollar funding round adds to Rivian's massive war chest

News Commentary | January 22, 2021

Rivian's $2.65 billion funding round comes just six months after the company raised $2.5 billion from mostly the same investors. Rivian is the most well‑funded BEV startup at this point, as it has raised a total of roughly $8 billion dollars, include raising more than $2 billion in 2019, 2020, and ... To read more, click here.